Akeso to Present Ivonescimab Phase III Overall Survival Data at ESMO Congress
Akeso, Inc. announced its Ivonescimab Phase III overall survival data for biliary tract cancer has been selected as a late-breaking abstract for ESMO 2026. Nearly 30 Akeso studies will be presented at the event.
Akeso, Inc. has announced that its drug Ivonescimab has been selected for presentation as a late-breaking abstract at the European Society for Medical Oncology (ESMO) 2026 Congress. The study evaluated the efficacy of Ivonescimab as a first-line treatment for biliary tract cancer, focusing on overall survival outcomes.
The congress, taking place this year, will feature presentations of nearly 30 clinical studies from Akeso, highlighting the company's globally first-in-class bispecific antibodies. Beyond Ivonescimab, these studies cover various therapeutic areas where Akeso is actively conducting research.
Biliary tract cancer is a rare and aggressive form of cancer with historically limited treatment options. Emerging therapies like Ivonescimab, which offer targeted approaches to cancer cells, provide potential new avenues for patients diagnosed with this condition. The ESMO Congress is a significant event in the oncology field, with selected presentations often representing the latest advancements and promising findings.
The selection of Ivonescimab for a late-breaking abstract at ESMO 2026 underscores its potential as a significant therapeutic option for challenging cancers. Akeso continues its research and clinical development efforts to advance its drug pipeline and bring new treatments to patients.